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Abstract
Background: Buruli ulcer (BU) is a neglected necrotizing disease of the skin, subcutaneous tissue and bone, caused by
Mycobacterium ulcerans. BU pathogenesis is associated with mycolactone, a lipidic exotoxin with cytotoxic and
immunosuppressive properties. Since 2004, the World Health Organization recommends the treatment of BU with a
combination of rifampicin and streptomycin (RS). Histological analysis of human tissue samples suggests that such
antibiotic treatment reverses the mycolactone-induced local immunosuppression, leading to increased inflammatory
infiltrations and phagocytosis of bacilli.
Methodology/Principal Findings: We used a mouse model of M. ulcerans footpad infection, followed by combined RS
treatment. Time-lapsed analyses of macroscopic lesions, bacterial burdens, histology and immunohistochemistry were
performed in footpads. We also performed CFU counts, histology and immunohistochemistry in the popliteal draining
lymph nodes (DLN). We observed a shift in the cellular infiltrates from a predominantly neutrophilic/macrophagic to a
lymphocytic/macrophagic profile in the infected footpads of antibiotic-treated mice. This shift occurred before the
elimination of viable M. ulcerans organisms, which were ultimately eradicated as demonstrated by the administration of
dexamethasone. This reduction of bacillary loads was accompanied by an increased expression of inducible nitric oxide
synthase (NOS2 or iNOS). Predominantly mononuclear infiltrates persisted in the footpads during and after treatment,
coincident with the long persistence of non-viable poorly stained acid-fast bacilli (AFB). We additionally observed that
antibiotherapy prevented DLN destruction and lymphocyte depletion, which occurs during untreated experimental
infections.
Conclusions/Significance: Early RS treatment of M. ulcerans mouse footpad infections results in the rapid elimination of
viable bacilli with pathogen eradication. However, non-viable AFB persisted for several months after lesion sterilization. This
RS regimen prevented DLN destruction, allowing the rapid re-establishment of local and regional cell mediated immune
responses associated with macrophage activation. Therefore it is likely that this re-establishment of protective cellular
immunity synergizes with antibiotherapy.
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Introduction
Buruli ulcer (BU), caused by the environmental pathogen
Mycobacterium ulcerans, is a necrotizing disease of the skin,
subcutaneous tissue and bone. This disease is the third most
common mycobacterial infection in the world, after tuberculosis
and leprosy. There has been a growing incidence of BU over the
last decade mainly in West African countries, which contributes
for the importance of this infection as an emerging infectious
disease [1,2]. The pathogenesis of BU is associated with
mycolactone, a lipidic exotoxin produced by M. ulcerans that has
cytotoxic and immunosuppressive properties [3–7].
Until recently, surgical excision of lesions and skin grafting was
the only available treatment for BU patients, but recurrence rates
varied from 6 to 47% [8–10]. In addition, surgery is not reliable in
rural poor regions, where the disease is endemic, due to lack of
medical care, high costs and prolonged hospitalization [2]. Since
2004, the World Health Organization (WHO) recommends a
combination of the antibiotics rifampicin and streptomycin (RS)
for the treatment of BU [11]. This recommendation was based on
the successful results obtained in a small clinical trial carried on
from 2001 to 2002 in Ghana with patients with early non-
ulcerative lesions [12], and following promising studies showing
bacterial killing in M. ulcerans–infected mice treated with
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rifampicin and an aminoglycoside (amikacin or streptomycin) [13–
15]. Subsequent clinical trials with higher numbers of patients
established the efficacy of the treatment in curing early lesions and
arresting or reducing the surface area of more advanced ones often
only requiring minimal surgery [16,17]. A recent study reports
healing in 95% of the patients with all forms of the disease treated
with RS without surgery, although a long time of therapy is
needed for the healing of some advanced cases [18]. The fact that
the RS treatment protocol still presents several limitations justifies
the need of furthering our understanding on the mechanisms
involved in M. ulcerans control, both in treated patients as well as
during the natural progression of the disease.
Histological features of advanced experimental and BU lesions
are characterized by extensive necrotic, acellular areas with clumps
of extracellular bacilli surrounded by a band of inflammatory
infiltrates composed mainly by neutrophils and macrophages, some
with intramacrophage bacteria [19,20]. In addition, it was recently
reported that during mouse footpad infections with virulent M.
ulcerans, pathogen-specific gamma interferon (IFN-c)-producing T
cells develop early in the draining lymph node (DLN) and that
CD4+ T cells migrate to the infection foci [21]. However, the
progression of infection is accompanied by the local depletion of
recruited cells; moreover, there is bacillary dissemination to the
DLN accompanied by mycolactone-induced extensive apoptotic
cytopathology, leading to depletion of CD4+ T cells and abrogation
of IFN-c expression [21] and/or activity [7]. This local and regional
immunosuppression compromises the maintenance of the early
initiated cellular mediated immunity (CMI) and allows the
progression of the disease in susceptible hosts [21]. On the other
hand, histological analysis of skin samples from BU patients after
completion of successful antibiotic treatment has suggested a
reversion of that local immunosuppression, based on the observa-
tion of abundant mononuclear infiltrates, including organized
lymphoid structures (granulomas and lymphoid clusters near vessels)
at the infectious focus [22]. It has been further suggested that these
inflammatory alterations occur early after the beginning of
antibiotherapy, being accompanied by phagocytosis of bacilli by
macrophages [23]. Also, when blood cells of patients treated with
antibiotics are stimulated, a higher IFN-c production is observed
[24]. This inflammatory and cytokine type of immune response is
characteristic of CMI and delayed-type hypersensitivity (DTH) that
are associated with resistance to M. ulcerans infection and with
spontaneous healing at later stages of the disease (reviewed in [25]).
Altogether, these observations in human studies suggest that a
CMI response would associate with the activity of the antibiotics
[22,23]. However, since in the previous studies no direct
correlations were addressed between alterations in histology and
bacterial viability in the same subjects, it remains unclear whether
the immune recuperation associated with efficient antibiotherapy
begins before or after the elimination of viable bacilli, which
depends on the timing of the host response not only in the
infection focus but also in the DLN.
In addition, persistence of acid fast bacilli (AFB) in the lesions has
been reported after the end of the treatment period, in both mice
and in humans [12,14,22,23,26,27], raising the question of M.
ulcerans being dead or only in a state of latency, as reported for
Mycobacterium tuberculosis [28,29]. This may have implications for our
understanding on the worsening of lesions or the appearance of new
lesions reported in RS-treated patients during or after treatment, the
so-called paradoxical reactions, that may be triggered either by M.
ulcerans antigens or by viable organisms [18,27,30–32].
We have therefore studied in the mouse footpad model of M.
ulcerans infection, during and after a RS regimen, the progression
of the infection, viability and eradication of bacteria, as well as the
dynamics of the cellular host immune responses in both the
footpad and the DLN.
Materials and Methods
Ethics Statement
This study was approved by the Portuguese national authority
for animal experimentation Direcc¸a˜o Geral de Veterina´ria (ID:
DGV 594 from 1st June 2010). Animals were kept and handled in
accordance with the guidelines for the care and handling of
laboratory animals in the Directive 2010/63/EU of the European
Parliament and of the Council.
Animals
Eight-week-old female Balb/c mice were obtained from Charles
River (Barcelona, Spain) and were housed under specific-
pathogen-free conditions with food and water ad libitum.
M. ulcerans experimental infection
M. ulcerans 98–912 (Institute of Tropical Medicine (ITM)
collection, Antwerp, Belgium), a mycolactone D producing strain,
was isolated in China from a case of ulcer and is highly virulent for
mice, as previously described [6,7,20]. Preparation of the inoculum
was performed as previously described [21]. Mice were inoculated in
the left hind footpad with 0.03 ml ofM. ulcerans suspension containing
5.5 log10 AFB. The right hind footpad was used as a control.
Treatment of mice
Rifampicin and streptomycin were obtained from Sigma-
Aldrich (USA). The dose and mode of administration were
adapted from previous studies that used a mouse model of M.
ulcerans infection [33,34]. Briefly, rifampicin was given orally by
gavage at a dosage of 10 mg/kg of body weight. Streptomycin was
given by subcutaneous injection, at a dosage of 150 mg/kg of body
weight. The treatment was initiated at the second week post-
infection when the footpads of mice were swollen to 2.5 mm and
was performed 6 days per week during 10 weeks. Antibiotic
vehicles were given to control mice.
Immunosuppressive treatment
Dexamethasone (Sigma-Aldrich) administration was adapted
from a previous study that used a mouse model of reactivation of
latent M. tuberculosis [29]. Briefly, dexamethasone was given by
intraperitoneal injection at a dosage of 5 mg/kg of body weight.
The administration was initiated at week 9 after the end of antibiotic
treatment, and given 6 days per week for 10 weeks. Dexamethasone
vehicle was given to control antibiotic treated mice.
Assessment of footpad swelling and bacterial growth
After infection, as an index of lesion development, footpad
swelling of infected mice was determined over time, as previously
described [20]. The non-treated mice were sacrificed after the
emergence of ulceration at 24 days post-infection, and no further
parameters were evaluated for this group. M. ulcerans growth in
footpad tissues of infected mice and in popliteal DLN that drains the
infected footpad, was evaluated by colony forming units (CFU) and
AFB counts at 15, 24, 42, 81, 143 and 217 days post-infection.
Footpads were homogenized as previously described [20]. At this
time, samples for AFB counts were collected and determined
according to the method described by Shepard and McRae [35].
Suspensions were decontaminated with hydrochloric acid (HCl)
1 M containing 0.001% phenol red solution for 15 min., followed
by neutralization with sterile sodium hydroxide 1 M. Suspensions
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were centrifuged and ressuspended in PBS. DLN were homoge-
nized and the cell suspensions were lysed with saponin 0.1%. Serial
dilutions of the footpad and DLN homogenates were plated on 7H9
agar. CFU’s were counted after 6–8 weeks of incubation at 32uC.
Flow cytometry
Single cell suspensions of the popliteal DLN were stained with a
combination of fluorochrome-labeled monoclonal antibodies
specific for CD3 (clone 145-2C11, BD Pharmingen, USA) and
CD19 (clone 1D3, BD Pharmingen), for 20 min. at 4uC. Cells
were fixed overnight with 2% formalin in PBS with 0.5% BSA and
0.01 M azide (Sigma) and analyzed using BD FACSDivaTM
version 6 software on a Becton Dickinson LSR II flow cytometer.
Histological and immunofluorescence studies
Mouse popliteal DLN and footpads were harvested, fixed in
buffered formalin and embedded in paraffin. Light-microscopy
studies were performed on tissue sections stained with hematoxylin
and eosin (HE) or Ziehl Neelsen (ZN), as previously described
[20]. The histological analysis of mouse footpads was performed
by the identification of the type of predominant inflammatory
infiltrate (when present) in each field of 406objective, attributing
the classifications of ‘‘predominantly mononuclear’’ or ‘‘predom-
inantly ‘‘neutrophilic’’. The relative abundance of inflammatory
cells in the infiltrates was classified as scarce (1), intermediate (2) or
abundant (3) using a 406 objective. The distribution of AFB was
classified as ‘‘predominantly intracellular’’ or ‘‘predominantly
extracellular’’, depending on the localization of the majority of
bacteria in each field, using a 1006 objective.
For immunofluorescence staining, tissue sections were deparaffi-
nised and hydrated. Antigen retrieval was performed with Citrate
Buffer (Lab Vision Corporation, USA) for 20 min. For the detection
of germinal centers in DLN, FITC fluorochrome-labeled peanut
agglutinin (PNA) (Sigma) was added to the sections at a concentration
of 1:100 for 2 h at room temperature. For the detection of the
enzyme inducible nitric oxide synthase (NOS2) in the footpads,
tissues were incubated with purified rabbit polyclonal NOS2 (clone
M-19) (Santa Cruz Biotechnology, USA) at a concentration of 1:100
followed by overnight incubation at 4uC. Goat anti-rabbit Alexa-
Fluor 568 secondary antibody (Molecular Probes, USA) was added
at a concentration of 1:500 for 1 h at room temperature. Afterwards,
for the detection of M. ulcerans, NOS2 stained sections were
incubated with Auramine-O (Polysciences, Inc., USA) for 30 min.
at room temperature and decolorized with 0.5%HCl fuming 37% in
absolute ethanol. For all sections, DAPI (4¢,6-diamido-2-phenylin-
dole hydrochloride, Molecular Probes) was used to detect nuclei.
Images were obtained with an Olympus BX61 microscope.
Statistical analysis
Differences between the means of experimental groups were
analyzed with the two-tailed Student’s t test, with a 95% level of
significance, using the GraphPad Prism version 5.0 software. For
percentage values, the statistical analysis was performed after
transforming them to arcsine values. Differences with a P
value,0.05 were considered significant.
Results
Highly virulent M. ulcerans is eradicated from the footpad
following RS treatment while non-viable bacilli persist for
several months
We subcutaneously infected mouse footpads with 5.5 log10 AFB
of the highly virulent M. ulcerans strain 98–912 and started
antibiotic treatment at the second week post-infection, when
footpad swelling had reached 2.5 mm (Figure 1A) and bacterial
growth 4.91 log10 CFU’s (Figure 1B). In non-treated mice we
observed progression of footpad swelling to around 4.2 mm in 4
weeks (Figure 1A), time point at which mice started showing signs
of ulceration, while in treated mice the progression of swelling was
halted after only one week of RS treatment (Figure 1A).
Furthermore, we observed a progressive reduction of footpad
swelling until normal values by the end of the treatment period,
which was maintained until the end of the experimental period, 5
months later (Figure 1A). The reduction of footpad lesions
correlated with a significant decrease in CFU counts (P,0.001),
observed as early as two weeks of treatment (Figure 1B). By 42
days post-infection and until the end of the experimental period
(82, 143 and 217 days post-infection) CFU counts were
undetectable (Figure 1B).
Interestingly, comparative analysis of CFU and AFB values
(Figure 1B and 1C) showed that non-culturable bacilli identified by
AFB ZN staining only started to decline by the end of the
treatment period (82 days post-infection) and persisted for several
months in the footpad tissue (Figure 1C). Indeed, 9 and 20 weeks
after the end of treatment (143 and 217 days post-infection,
respectively), we still found AFB in treated mice (Figure 1C).
However, while in non-treated mice the acid-fastness (as assessed
by ZN) of approximately half of bacilli remained normal
throughout infection (data not shown), in antibiotic-treated
animals the acid-fastness faded over time, with the predominance
of beaded and poorly stained (ghost) bacilli (P,0.001 from 12 to
21 days and from 42 to 82 days post-infection) (Figure 1 D and F).
To assess if the AFB persisting in the footpad tissue of treated
mice corresponded to dead bacteria, we used an adapted protocol
of the Cornell model [29]. Corticosteroid administration was
performed during 10 weeks, starting at week 9 after the end of RS
treatment. In contrast to what happens in the M. tuberculosis model
of latency [28,29], we did not observe reactivation of M. ulcerans
infection as viable bacilli were not detected, despite the persistence
of AFB (Table 1).
Antibiotic treatment is associated with a re-
establishment and maintenance of the early-developed
local mononuclear inflammatory response to M. ulcerans
Histopathological analysis showed edematous and necrotic
lesions (Figure 2A) already established in the footpad tissue when
the RS treatment was initiated. As previously described in M.
ulcerans progressing lesions from humans and mice [19,20],
necrosis was surrounded by an inflammatory infiltrate composed
mainly by macrophages and neutrophils (Figure 2A, 2B, 2C, 3C
and 3D). These necrotic areas contained clumps of extracellular
bacilli (Figure 2D), whereas in peripheral infiltrates intracellular
bacteria were predominantly seen (Figure 2E). Extensive edema
was also evident (Figure 2A and 1A). After starting RS treatment
at day 12 post-infection, we observed an increase of inflammatory
infiltrates as early as week 3 post-infection (Figure 2J and 3E;
P,0.001), accompanied by a switch to a profile with a
predominance of lymphocytes and macrophages (Figure 2K, 3C
and 3D; P,0.001). Despite the persistence of necrotic areas
(Figure 2J) with some extracellular bacilli (Figure 2N), mononu-
clear cells were now present in these areas (Figure 2L). We also
observed a higher percentage of areas with intracellular bacilli
(Figure 3A; P,0.05), which were mainly found in the peripheries
of the remaining necrotic tissue (Figure 2M). In contrast, at the
same time point, non-treated mice showed an increase of tissue
areas with clumps of extracellular bacilli (Figure 2I and 3B;
P,0.05), correlating with the expansion of necrotic areas and the
Cellular Immunity to M. ulcerans and Antibiotics
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emergence of footpad ulceration (Figure 2F). Nevertheless, some
peripheral phagocyte-rich infiltrates could still be found (Figure 2G
and 2H).
At the last week of RS treatment, footpad tissues were almost
devoid of necrotic areas (Figure 2O), although some histological
sections revealed a disorganized tissue, invaded by mononuclear
Figure 1. Lesion progression and bacterial proliferation of M. ulcerans in the footpads of mice treated or non-treated with RS. Mice
were infected with M. ulcerans strain 98–912 and were left untreated (closed circles) or subjected to treatment with RS for 10 weeks (open circles). (A)
Lesion progression was assessed by measurement of footpad swelling (n = 15). Bacterial proliferation was assessed by CFU (B) and AFB counts (C)
(n = 5). (D) Percentage of well stained (black bars) versus poorly stained (including beaded) (grey bars) AFB in the footpad for the antibiotic treated
group of mice. At day 12 post-infection, treatment was initiated until day 82. (E) AFB at day 12 post-infection, with well stained (arrowheads) and
beaded (arrow) bacilli. (F) AFB at day 156 post-infection, with beaded (arrow) and poorly stained (triangle) bacilli. Asterisks represent significant
differences between treated and non-treated mice on panels B and C (**, P,0.01, ***, P,0.001). Significant differences over time for the well stained
or poorly stained group in panel D were determined by comparing each time point with the following (***, P,0.001). Grey bar on panels A, B and C
represents the time period of antibiotic administration. d.l., detection limit; n.d., not detected. {, mice were sacrificed for ethical reasons after the
emergence of ulceration. Results are from one representative experiment of two independent experiments. Data points and bars represent the mean
6 SEM.
doi:10.1371/journal.pone.0032740.g001
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cells (Figure 2Q) and co-localized with extracellular bacilli
(Figure 2S). However, the extracellular bacilli, as well as bacteria
localized at the peripheral zones with cellular infiltrates
(Figure 2R), were poorly stained, which is consistent with the
absence of detectable CFU (Figure 1B) and presence of beaded
and ghost AFB in the tissue homogenates (Figure 1C, 1D and 1F).
In addition, the maintenance of extensive inflammatory infiltrates,
mainly composed by mononuclear cells, was observed (Figure 2P,
2Q, 3C and 3E). This infiltrate persisted 5 months after the end of
the treatment (Figure 2T, 2U, 3C and 3E), coincident with the
persistence, although decreased, of tissue areas containing poorly
stained AFB, observed both intra and extracellularly (Figure 2V,
3A and 3B).
Efficient elimination of M. ulcerans by RS treatment is
associated with activation of macrophages
Phagocytes, in particular macrophages, are the main effector
cells involved in mycobacterial phagocytosis and intracellular
killing. One of the mechanisms of mycobacterial killing is the
production of nitric oxide (NO) in the macrophage phagosome,
mediated by the iNOS (or NOS2) [36–38]. The expression and
production of this enzyme in macrophages is, in turn, largely
mediated by the IFN-c-dependent pathway [37,39,40]. It was
previously shown that NO production is important for M. ulcerans
killing within macrophages [7]. Therefore, as a marker of
phagocyte activation, we were prompted to evaluate by immuno-
histochemistry the presence of NOS2 at the site of M. ulcerans
infection, both during and after antibiotic treatment. Before the
beginning of RS treatment, at day 12 post-infection (Figure 4A),
we did not find staining for NOS2 in the footpad areas with bacilli
clumps (Figure 4B), and, at the periphery of infectious focus,
NOS2 staining was very scarce, with only a few positive
inflammatory cells (Figure 4C).
At the emergence of ulceration in non-treated mice (day 21
post-infection), larger areas with clumps of bacilli were observed
(Figure 4D and F), and, again, NOS2 staining was absent, as well
as in the peripheral areas (Figure 4E). On the other hand, at the
same time point, RS-treated mice presented footpad tissue with
NOS2 staining (Figure 4G and 4H), particularly in areas with few
or absent bacilli (Figure 4I), as compared to regions with higher
bacilli numbers (Figure 4J). At the end of the treatment period (82
days post-infection) numerous and larger NOS2-positive areas
were seen (Figure 4K) in regions with few or absent AFB
(Figure 4L), and fewer NOS2-positive cells were found in the
areas with increased bacterial load (Figure 4M). Interestingly, 5
months after the end of the treatment (Figure 4N), areas with
NOS2 were still present and appeared co-localized with AFB
(Figure 4O).
Early antibiotic treatment prevents DLN destruction
induced by colonization with M. ulcerans
Lymphocytes recruited to the site of infection are initially
differentiated and activated in the DLN; therefore, characteriza-
tion of adaptive immune responses in this lymphoid organ is
essential to disclose host mechanisms of protection. Previous
studies from our laboratory showed that the initial increase of the
total number of cells, including B and T cells, in the popliteal DLN
upon footpad infection by M. ulcerans strain 98–912 is followed by
a rapid decrease of cell numbers [21]. This profile was confirmed
in this study (Figure 5A, 5B and 5C), with a significant increase of
the total number of cells from day zero to day 14 (P,0.05),
followed by a significant decrease in the number of total cells at
day 21 post-infection (P,0.01). This decline is related to the
colonization of DLN by viable bacteria (as observed in Figure 5D)
that induce apoptotic cell death associated with the production of
mycolactone, as previously described [21].
We now show that antibiotherapy resulted in the prolonged
maintenance of cells in the DLN (Figure 5A, 5B and 5C), as we did
not observe statistical significant differences over time since the
beginning of the treatment, which was correlated with a clearance
of CFU counts in the DLN (Figure 5D). Analysis of histopathology
21 days post-infection showed that in non-treated animals, the
structure of the DLN was damaged, with the depletion of cells and
the absence of organized germinal centers (Figure 5G and 5H) that
preceded footpad ulceration, as previously described [21], while in
treated animals the structure of the DLN was maintained
(Figure 5I and 5J). After 4 weeks of treatment, when viable bacilli
were already absent from the footpad (Figure 1B) and from the
DLN (Figure 5D), germinal centers were not seen in the
histological sections of DLN (Figure 5L), indicating that this
lymphoid organ returned to its steady state structure.
Discussion
Since the recommendation by WHO in 2004 of treating BU
patients with a regimen of antibiotherapy combining RS, clinical
studies gave rise to the hypothesis that a synergistic effect between
antibiotics and the host immune system is in place to clear M.
ulcerans infection [18,22,23]. RS are bactericidal against extracel-
lular and intramacrophage susceptible mycobacteria [41] and the
quick reduction in M. ulcerans CFU counts in treated mice
([14,42,43] and present results) suggests that such mode of
antimycobacterial activity also operates in vivo. However, the
possible participation of the host immune system in the control of
the infectious process remains an open question. Considering the
limitations of human studies, experimental infections performed in
animal models constitute a crucial contribution for a detailed
investigation on the host immune response to M. ulcerans during
antibiotherapy. This approach may well open the possibility of
immune-based interventions for the treatment of BU as an
alternative or a complement to the current RS protocol. Indeed,
the WHO RS protocol presents several limitations, including the
insufficient response of advanced lesions [44], the long period of
administration of intramuscular streptomycin leading to poor
compliance as it demands skilled personnel and is accompanied by
adverse side effects (especially ototoxic effects) [17,18], and the
occurrence of paradoxical reactions characterized by the worsen-
ing of lesions or the appearance of new lesions [18,27,30–32].
Additionally, the study of the host immune response to M. ulcerans
during RS may help advance the knowledge of immune-mediated
mechanisms of protection operating in antibiotic-treated hosts.
Using a mouse model of footpad infection with a highly virulent
strain of M. ulcerans, we herein show that a curative RS regimen is
Table 1. Dexamethasone administration did not reactivate M.
ulcerans infection in mice previously treated with antibiotics.
Day of DEX1 treatment Group CFU AFB
0 Control Not detected 5.09 log1060,25
74 Control Not detected 4.09 log1060,61
DEX Not detected 4.07 log1060,64
Antibiotic treated mice were left for a period of 8 weeks, and then subjected to
dexamethasone1 administration during 10 weeks (74 days). Bacterial load was
determined by CFU and AFB counts at the beginning and at the end of
administration. Values are mean 6 standard deviation.
doi:10.1371/journal.pone.0032740.t001
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associated with alterations in the histopathological pattern at the
infectious focus, suggesting a waning of the mycolactone-
dependent immunosuppressive state that follows an early and
transient local CMI response [21]. This reversion allows the
reinforcement of the host cellular immune response and the
activation of macrophages, accompanying the quick reduction in
the number of viable bacilli. In addition, RS treatment is
associated with the rapid reduction in viable M. ulcerans numbers
in the DLN and development and maintenance of CMI in this
lymphoid organ.
Our observations in the mouse model share features with the
histopathological findings reported for BU treated patients
[22,23], although accelerated in time. Indeed, mixed cellular
infiltrations with intracellular bacilli surrounding areas of necrosis
with extracellular bacilli are also seen in patients’ ulcers after 4
weeks of treatment, [23], comparable to what is observed in mouse
footpads after 2 weeks of treatment. In treated patients, only at 8
weeks of treatment macrophage/lymphocyte predominant infil-
trates and intra and extracellular bacterial debris were reported
[22,23], as is the case of footpads already at 4 and 8 weeks post-
treatment. Regarding the descriptions of pre-ulcerative lesions in
humans, abundant macrophage/neutrophil infiltrates are pre-
dominant at 4 weeks of treatment, with a large proportion of
bacteria inside phagocytes [23]. In line with this, our mouse
histological analysis suggests that antibiotherapy is associated with
a shift in the type of inflammatory infiltrates from neutrophil/
macrophage-predominant to macrophage/lymphocyte-predomi-
nant, associated with the enhancement of M. ulcerans phagocytosis.
The fact that the histological alterations associated with RS
antibiotherapy are observed earlier in the mouse model may be
correlated with the smaller size of lesions. Additionally, the
treatment in mice is initiated when the lesions are still in an early
stage. Therefore, the antibiotics may reach the core of the lesion
easier and faster in mice than in patients.
Figure 2. Histology of mice footpads infected with M. ulcerans and treated or non-treated with RS. Histological sections of footpads
collected at different time points were stained with HE (A, B, C, F, G, J, K, L, O, P, Q, T and U) or ZN (D, E, H, I, M, N, R, S and V). Magnifications:610 (A, F,
J, O and T),660 (B, C, G, K, L, P, Q and U) and6100 (D, E, H, I, M, N, R, S and V). At day 12 post-infection, treatment was initiated until day 82. (A and F)
Footpads of non-treated mice (at 12 and 21 days post-infection, respectively) with necrotic areas (asterisks). Magnifications of panel A and F
(rectangles) show neutrophils (B and G; arrowheads) and mononuclear cells (C and G; arrows) at the periphery of necrotic areas. (D and I) Clusters of
extracellular bacilli in necrotic areas. Intracellular bacilli (E; arrowheads), and intra (H; arrowhead) and extracellular bacilli (H) are observed at more
distant regions from necrotic areas at 12 and 21 days post-infection, respectively. (J, O and T) Footpads of antibiotic treated group of mice at 21, 82
and 245 days post-infection show abundant cellular infiltration, composed mainly by mononuclear cells (K, P and U; arrows), and few scattered
neutrophils (K; arrowhead). Necrotic areas are reduced in panel J and O (asterisk). Magnifications of those areas (rectangles) show the presence of
mononuclear cells (L and Q, arrows). A predominance of extracellular bacilli is found in those areas (N and S), and intracellular bacilli are present at
more distant regions (M and R; arrowheads). (V) Tissue shows few, scattered bacilli (arrowheads) in areas of cellular infiltration. Results are from one
representative experiment of two independent experiments.
doi:10.1371/journal.pone.0032740.g002
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A previous study showed that an early T cell-mediated immune
response is developed in mice upon infection with M. ulcerans, with
migration of pathogen-specific CD4+ T cells from the DLN to the
site of infection [21]. However, progressive infection leads to the
depletion of these cells by mycolactone-dependent local destruc-
tion [21], resulting in persistence of neutrophilic infiltrates in the
lesion [20]. Subsequently, T cell depletion by the same mechanism
also occurs in the DLN, due to the node colonization by viable
mycolactone-producing M. ulcerans [21]. Here we show that early
RS chemotherapy prevents DLN destruction and depletion of T
and B cells, which may allow the maintenance of lymphocyte
activation and migration to the site of infection. This may have an
important role in the switch of the inflammatory pattern observed
in the lesion soon after the beginning of treatment, due to the
reversion of the local immunosuppression by the antibiotic-
induced killing of mycobacteria, which, in turn allows the
recruitment and survival of activated lymphocytes in the footpad,
and the re-establishment of a local CMI. The data regarding the
presence of NOS2 only in treated footpads support this
interpretation. As previously described [20,21,25], CMI responses
are protective against M. ulcerans infections, as is the case with
other mycobacteria, and IFN-c was found to activate macrophag-
es, through phagolysosome fusion and NO production, with the
boosting of their activity against M. ulcerans; an effect that is
abrogated by mycolactone [7].
Comparing CFU and AFB counts for non-treated mice, we
conclude that in untreated lesions numerous M. ulcerans bacilli
visible by microscopy are non-culturable, an observation that is in
accordance with previous reports on mice and humans infected
with M. ulcerans [12,15,26] or Mycobacterium leprae [45]. As
previously reported in studies of both murine and human M.
ulcerans infections [12,14,15,33], the antibiotherapy-associated
decline in cultivable bacilli is not paralleled by a corresponding
decline in the number of AFB; number that in our study was
maintained during the 10 weeks of treatment, before starting to
decrease. In the case of M. tuberculosis infection, reports in mice
suggest that non-culturable bacilli, observed during and after
treatment are not dead, but rather in a state of latency, as
spontaneous reactivation may occur or by corticosteroid admin-
istration [28,29,46,47]. However, in our model, the fact that the
M. ulcerans bacilli have an altered morphology suggests degradation
after bacterial killing, as also reported in humans [22,23,32]. This
hypothesis was confirmed by the non-reactivation of infection after
treatment, including after corticosteroid administration, which
demonstrates that bacilli are effectively dead. The persistence of
AFB thus indicate that the degradation and complete clearance of
dead bacteria by macrophages is largely delayed, which may be
due to the difficulty of incoming phagocytes to access the necrotic
areas where most extracellular bacilli accumulate. Alternatively,
sufficient amounts of mycolactone could be still present at these
sites [48], inhibiting the activity of phagocytes. This hypothesis is
also supported by the low presence of NOS2 at the sites of higher
bacillary content. In addition, the persistence of AFB further
indicates that the assessment of antibiotherapy efficacy by AFB
counts is inadequate, as previously suggested [14,33]. On the other
hand, the prolonged permanence of AFB in tissues explains the
Figure 3. Histological analysis of mice footpads infected with M. ulcerans and treated or non-treated with RS. Histological sections of
footpads collected at different time points post-infection were stained with HE or ZN and the percentage of fields with AFB localized predominantly
inside (A) or outside (B) cells and the percentage of fields with predominance of mononuclear (C) or neutrophilic cells (D) was evaluated. (E) Relative
abundance of inflammatory infiltrates. Analyses were performed in 6 different sections of each sample of mice footpad, in a total of 3 footpads per
group. Asterisks represent significant differences between treated and non-treated mice at 21 days post-infection (*, P,0.05; ***, P,0.001).
Significant differences over time for the non-treated or RS group were determined by comparing each time point with the following (*, P,0.05;
**, P,0.01, ***, P,0.001). NT; non-treated mice. RS; mice treated with rifampicin and streptomycin. Time points represented are days post-infection.
Treatment duration was as described in Figure 2 legend. Data bars represent the mean 6 SEM.
doi:10.1371/journal.pone.0032740.g003
Cellular Immunity to M. ulcerans and Antibiotics
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e32740
persistence of inflammatory infiltrates with activated NOS2-
producing phagocytes, found more than one year after the end
of the treatment (data not shown).
Although we did not find evidence for pathological effects
associated with this prolonged inflammatory response in our
mouse model, neither by macroscopic or histological analysis, our
findings are in line with the observations of immune-mediated
paradoxical reactions in humans, characterized by the worsening
of treated lesions or by the appearance of new lesions during or
after treatment. Indeed, these pathological reactions in patients
submitted to RS chemotherapy are histologically characterized by
an abundant inflammatory response and degraded bacteria
[27,30,32]. Therefore, experimental studies should be developed
in animal models to modulate paradoxical reactions in order to
clarify if a down-regulation of this immune response or the surgical
removal of the lesion core may control this type of reaction.
In summary, we conclude that the early treatment of murine M.
ulcerans infection with an antibiotic regimen adapted from the
WHO protocol is responsible for the waning of the local/regional
state of immunosuppression induced by mycolactone, which is
observed before the complete clearance of viable bacilli. This
further suggests that the rapid re-establishment of the host immune
response, through the rescue of DLN function, may participate in
the clearance of infection and/or in the resolution of infection-
associated histopathology. We also found that poorly stained AFB
persist for many months after antibiotherapy at the infection focus
and that these bacilli are dead, although capable of inducing a
long-term inflammatory response. These observations give insights
Figure 4. Immunohistochemistry for NOS2 of mice footpads infected withM. ulcerans and treated or non-treated with RS. Histological
sections of footpads collected at different time points were stained with DAPI (blue; nuclei staining), anti-NOS2 antibody (red) and auramine-O
(green; mycobacteria staining). Magnifications610 (A, D, G, H, K and N) and640 (B, C, E, F, I, J, L, M and O). Treatment duration was as described in
Figure 2 legend. (A) Footpads of non-treated mice at 12 days post-infection with no evidence for NOS2 presence in the tissue in areas with numerous
bacilli (B, green) and only few cells are stained at peripheries (C). (D) At 21 days post-infection huge clumps of bacilli are observed with no evidence
for NOS2 staining (F), which is neither present at the periphery (E). (G and H) Footpads of mice treated with RS at 21 days post-infection show little
NOS2 staining in areas co-localized with few (J) or absent bacilli staining (I). (K) Footpads of mice treated with RS at 82 days post-infection show more
numerous and larger areas of NOS2 with little co-localization with bacilli (L), whereas areas with numerous extracellular bacilli show little staining for
NOS2 (M). (N and O) Footpads of mice treated with RS at 5 months after finalizing the treatment (245 days post-infection) show NOS2 staining co-
localized with bacilli. Results are from one representative experiment of two independent experiments.
doi:10.1371/journal.pone.0032740.g004
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Figure 5. Leukocyte kinetics, bacterial proliferation and DLN histology of mice infected with M. ulcerans and treated or non-treated
with RS. (A) Total number of leukocytes in the DLN were determined at different time points post-infection in non-treated (closed circles) and
antibiotic-treated mice (open circles) (n = 5). (B) Total number of B cells (CD19+) and (C) T cells (CD3+) in the DLN were determined by flow cytometry
(n = 5). (D) Bacterial proliferation was assessed by CFU counts; d.l., detection limit; n.d., not detected. Significant differences between values over time
in non-treated or treated mice on panel A, B and C were determined by comparing each time point with the following (*, P,0.05; **, P,0.01).
Significant differences between treated and non-treated mice on panel D (***, P,0.001). Grey bar represents the time period of antibiotic
administration. Histological sections of DLN collected at different time points were stained with HE (E, G, I and K) or with FITC fluorochrome-labeled
PNA (green) counterstained with DAPI (blue; nuclei staining) for the labeling of germinal centers (F, H, J and L). Magnifications64. (E and I) DLN of
non-treated mice at day 12 and treated mice at day 21 post-infection, respectively, showing enlargement of the DLN with germinal centers (F and J).
(G) DLN of non-treated mice at day 21 post-infection showing extensive cell depletion and the absence of germinal centers (H). (K) DLN of treated
mice at day 42 post-infection showing a normal structure and absence of germinal centers (L). Results are from one representative experiment of two
independent experiments. Data points represent the mean 6 SEM.
doi:10.1371/journal.pone.0032740.g005
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on the inflammatory nature of the paradoxical reactions to RS
treatment recently described in BU patients [18,27,30–32]. Future
studies are needed for the improvement of the available non-
surgical therapeutical approaches against BU, which should target
not only antimicrobial activity but also immunomodulation,
aiming at potentiating bactericidal activity as well as controlling
the exacerbated inflammatory responses.
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